Evaluation of Cholecalciferol Efficacy in the Management of Secondary Hyperparathyroidism in Hemodialysis Patients

Authors

  • Hamad Ahmad Khan, Muhammad Naeem, Noman Khan Gandapur, Fouzia Jameel, Jaweria Gul

DOI:

https://doi.org/10.53350/pjmhs22169544

Abstract

The deficiency of vitamin D is public among hemodialysis (HD) patients and is a key factor in the development of secondary hyperparathyroidism (SHPT). Secondary hyperparathyroidism is currently accomplished by lowering circulating phosphate levels with parathyroid hormone (PTH), vitamin D analogs, and oral binders. The current study aim was to assess the efficacy of cholecalciferol in the management of secondary hyperparathyroidism in hemodialysis patients with concomitant vitamin D deficiency/insufficiency. A total of 53 patients were taken with25 male and 28 female patients. After treating patients with cholecalciferol, serum PTH levels improved significantly, with mean pre-treatment levels of 486.99±191.10, which had decreased to a mean post-treatment level of 301.66±201.08. Serum Vitamin D levels also improved significantly, with mean pre-treatment levels of 10.86±4.98, which increased to a mean post-treatment level of 29.98±17.24. Patients treated with cholecalciferol had no significant change in phosphorous and calcium levels.

Keywords: Parathyroid Hormone; Cholecalciferol; Vitamin D; Secondary Hyperparathyroidism; hemodialysis; Pakistan

Downloads

How to Cite

Hamad Ahmad Khan, Muhammad Naeem, Noman Khan Gandapur, Fouzia Jameel, Jaweria Gul. (2022). Evaluation of Cholecalciferol Efficacy in the Management of Secondary Hyperparathyroidism in Hemodialysis Patients. Pakistan Journal of Medical & Health Sciences, 16(09), 544. https://doi.org/10.53350/pjmhs22169544